drugset / Trial / NCT04366232
Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation
Phase 2
Terminated
2 enrolled
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Assistance Publique Hopitaux De Marseille · collabHôpital d'instruction des armées Sainte-Anne · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
During SARS-Cov2 infection with serious respiratory implication and high systemic inflammation level, intravenous ANAKINRA alone or associated with RUXOLITINIB for severe cases might reduce inappropriate systemic inflammatory response, improve breathing and decrease occurrence or duration of ARDS and associated mortality.
Timeline
- Start
- 2020-08-19
- Primary completion
- 2020-10-02
- Completion
- 2020-10-02
Publications
- Results Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16. No abstract available.
- Results Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648. No abstract available.
- Results Zalinger ZB, Elliott R, Weiss SR. Role of the inflammasome-related cytokines Il-1 and Il-18 during infection with murine coronavirus. J Neurovirol. 2017 Dec;23(6):845-854. doi: 10.1007/s13365-017-0574-4. Epub 2017 Sep 11.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anakinra | Protein / enzyme biologic | 300 mg | Intravenous |
| Subject | Ruxolitinib | Small molecule | 5 mg | Oral |